NewTimeSpace News: HANSOH PHARMA announced that HS-10582 tablets, a Class 1 new drug independently developed by the Group, has received the Drug Clinical Trial Approval Notice from the NMPA, intended for clinical trials for the treatment of primary hypercholesterolemia and mixed dyslipidemia in adults, marking new progress in its R&D.
NewTimeSpace News: HAOHAI BIOTEC announced that its controlling subsidiary Saimaishi has obtained an NMPA medical device registration certificate for its trifocal toric IOL (valid until 3 August 2031), which passed the special review procedure for innovative medical devices and is the first domestically approved trifocal toric IOL in China; the Company has formed a high-end refractive IOL product matrix covering monofocal through multifocal toric correction; as the product has not yet generated sales, it will not materially affect near-term results.
On 6 August, the three major Hong Kong indices opened lower and declined throughout the day, with the Hang Seng Index down 1.49% to 25,530.28 points, the Hang Seng TECH Index down 2.28% and turnover of HKD 255.2 billion. On the trading front, the "twin titans" of large models strengthened against the trend, with MINIMAX-W (00100) surging 17.1% on its first day of formal admission to the connect and Z.AI (02513) up 4.42%; coal stocks led the gains, with YANKUANG ENERGY up 6.12%; gold stocks were active, with LINGBAO GOLD up 4.82%. Hong Kong insurance stocks were weak throughout the day, with AIA down 5.92%, dragged by rumors of taxation on gains from offshore policies. Southbound capital saw a net sell of HKD 1.461 billion. The HK Stock Connect list was adjusted today, with MINIMAX, Luxshare ICT and CCTC formally admitted.
On August 6, 2026, Hong Kong's three major indices declined across the board. The Hang Seng Index fell 1.49%, the Hang Seng Tech Index dropped 2.28%, and the Hang Seng China Enterprises Index declined 1.22%. Total turnover on the Hang Seng Index reached HKD 255.2 billion, while Southbound capital recorded a net outflow of HKD 1.461 billion.The large‑model sector bucked the trend, with MINIMAX‑W (00100.HK) surging over 17% on its first day of inclusion in the Stock Connect, and Z.AI (02513.HK) rising more than 4%.
NewTimeSpace News: SSY GROUP announced that four products received NMPA drug manufacturing registration approvals, all deemed to have passed the consistency evaluation; the Potassium Chloride Injection (II) represents the second domestic enterprise approval, further strengthening the therapeutic infusion layout in the ICU field; both Sodium Hyaluronate Eye Drops feature single-dose preservative-free packaging, forming a stratified dry eye treatment portfolio together with previously approved products; the approval of Metoclopramide Tablets marks the realization of API-to-formulation vertical integration.
NewTimeSpace News: On 6 August 2026, RoboSense (02498.HK) drifted lower in the afternoon. As at 15:37, the stock traded at HK$22.96, down 4.17%. The mandatory national standard Safety Requirements for Automated Driving Systems of Intelligent and Connected Vehicles issued by the MIIT has been officially released and will take effect on 1 July 2027.
NewTimeSpace (newtimespace.com) reported that on August 6, 2026, the chip theme retreated, with SMIC (00981.HK) fluctuating lower. As of 13:29, the stock was quoted at HKD 64.800, down 4.71%.
NewTimeSpace (newtimespace.com) reported that on August 6, 2026, the robotics theme showed choppy trading, with UBTECH (09880.HK) weakening. As of 13:16, the stock was quoted at HKD 87.300, down 1.85%.
NewTimeSpace News: Boan Biotech (06955.HK) announced on 5 August that the marketing authorization application for aflibercept biosimilar BA9101 has been filed in Brazil for wet AMD and diabetic macular edema. EYLEA recorded global sales of USD5.321 billion in 2025 and Brazil’s pharmaceutical market reached USD39 billion. Having obtained approval in China, the product is accelerating its overseas expansion.
NewTimeSpace News: Luye Pharma (02186.HK) announced that self‑developed new molecular entity LY03015, the world’s first VMAT2 inhibitor and Sigma‑1R agonist, has successfully completed a bridging clinical trial in the United States, supporting the upcoming efficacy‑oriented clinical trial in the US. Previous Phase II clinical data from China showed that the AIMS response rate reached 76.5% in the 20mg dose group, exceeding historical therapeutic benchmarks.
On August 5, 2026, The Hang Seng Index rose 0.24%, the Hang Seng Tech Index gained 0.97%, and the Hang Seng China Enterprises Index advanced 0.34%. Total turnover on the Hang Seng Index reached HKD 278.0 billion, while Southbound capital recorded a net outflow of HKD 1.398 billion.The AI chip and hardware sector led the gains strongly, catalyzed by Goldman Sachs' significant upward revision of revenue forecasts for domestic large models and a sharp rally in U.S. semiconductor stocks overnight. Biren Technology (06082.HK) surged over 12%, GigaDevice (03986.HK) gained more than 5%, and Hua Hong Semiconductor (01347.HK) and SMIC (00981.HK) followed suit.
NewTimeSpace (newtimespace.com) reported that on August 5, 2026, the chip theme strengthened, with HUA HONG GRACE (01347.HK) surging. As of 13:28, the stock was quoted at HKD 145.200, up 7.48%.
NewTimeSpace (newtimespace.com) reported that on August 5, 2026, the robotics theme continued to strengthen, while Midea Group (00300.HK) fluctuated lower. As of 13:13, the stock was quoted at HKD 96.400, down 0.57%.
NewTimeSpace News: Nanjing Leads Biolabs Co., Ltd. (09887.HK) announced that Oblenio Bio, the joint venture established with Aditum Bio, has completed first‑patient dosing in the Phase Ia first‑in‑human clinical trial of LBL‑051, a trispecific T‑cell engager targeting BCMA, CD19 and CD3. Pre‑clinical data demonstrated that LBL‑051 could achieve complete depletion of B‑cells and plasma cells via co‑targeting CD19 and BCMA with minimal cytokine release.
NewTimeSpace News: Jiangsu Hengrui Pharmaceuticals Co., Ltd. (01276.HK) announced that its subsidiaries have received the Drug Clinical Trial Approval Notice ratified and issued by NMPA. Phase II clinical trials are approved to evaluate SHR‑A2009 for Injection (HER3‑targeted ADC) in combination with adebrelimab, or in combination with third‑generation EGFR TKI, among patients with non‑small‑cell lung cancer. To date, no HER3‑targeted ADC has been approved globally for the treatment of NSCLC.
NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the New Drug Application for neoadjuvant therapy of Anitumab (KN026) co‑developed with Alphamab Oncology in combination with the Group’s self‑developed Docetaxel (Albumin‑Bound) for Injection (HB1801) for adult patients with early or locally advanced HER2‑positive breast cancer has been accepted by NMPA and included in the priority review and approval procedure. A pivotal Phase III study demonstrated that the combination regimen significantly improved the overall pathological complete response rate versus current standard‑of‑care treatment.
